Development · 9 Sep 2026
2 publishers have reported this development. Each act of reporting is below, cited.
Novartis India has entered into an Exclusive Promotion and Distribution Agreement with Novartis Healthcare for the distribution of Accentrix (ranibizumab) and Pagenax (brolucizumab) in India.
Novartis India entered into an exclusive promotion and distribution agreement with Novartis Healthcare Private Limited for the promotion and distribution of NHPL's retina portfolio comprising the products Accentrix and Pagenax in the Indian market.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.